Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

Authors :: de Guibert, Sophie
Dilhuydy, Marie-Sarah
Ysebaert, Loic
Sanhès, Laurence
Choquet, Sylvain
Aurran-Schleinitz, Therese
Guieze, Romain
Mahe, Beatrice
Daguindau, Nicolas
Araujo, Carla
Saad, Hussam
Ferrant, Emmanuelle
Cazin, Bruno
Feugier, Pierre
Dreyfus, Brigitte
Alain, Delmer
Lepretre, Stéphane
Le Garff-Tavernier, Magali
Lauren, Véronese
Schuh, Anna
Pereira, Bruno
Leblond, Veronique
Tournilhac, Olivier
Source :: Blood; December 2014, Vol. 124 Issue: 21 p3341-3341, 1p
Publication Year :: 2014
Abstract: de Guibert: Roche: Honoraria. Feugier:Roche: Honoraria. Schuh:Roche, Gilead, GSK, NAPP, Celgene: Honoraria. Leblond:Roche: Honoraria, Speakers Bureau. Tournilhac:mundipharma: Honoraria, Other, Research Funding; GSK: Honoraria, Other, Research Funding; Roche: Honoraria, Other, Research Funding.

Full Text Access

Tools